At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Tafasitamab and Lenalidomide for Diffuse Large B Cell Lymphoma. Active but no longer recruiting, targeting 53 participants across 62 sites in 9 countries.
Detailed Summary
This is an open-label, multicentre study too Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) who have had at least one, but no more than three prior systemic regimens and who are not eligible for high dose chemotherapy (HDC) with autologous stem-cell transplantation (ASCT) at the time of study entry.
Study Details
Timeline
Interventions
tafasitamab will be administered intravenously at protocol defined timepoints
lenalidomide will be administered orally at protocol defined timepoints